Lenovo Ships One Million Units from Its First European In-House Manufacturing Facility in Hungary
Lenovo (HKSE: 992) (ADR: LNVGY) has reached the milestone of manufacturing and shipping one million workstations and servers from its first purpose built in-house manufacturing facility in Europe, just over one year after it opened its doors in Budapest, Hungary.
After 10 months of construction during the pandemic, the facility opened in June 2022 to support customers throughout Europe, the Middle East, and Africa (EMEA) with their requirements for server infrastructure, storage systems and high-end PC workstations. As of June 2023, the facility has provided solutions to more than 1,000 customers in 69 countries and seen the scale and speed of operations accelerate over the past year. Over 180 customers have visited the site, enabling deeper collaboration, transparency and understanding with Lenovo customers across the EMEA region.
Szabolcs Zolyomi, Factory Site Leader at Lenovo, commented: “Opening the Hungary facility was an important milestone for Lenovo, extending our international manufacturing operations and representing significant economic potential for both the private and public sectors in the country. The achievement of shipping one million units is testament to the past year of internal and external collaboration with our employees and customers. We have been able to respond to customer needs more effectively, with greater efficiency and control over product development and supply chain operations, all while continuing our commitment to sustainability and supporting the local community.”
Since opening, the site has seen a 20% increase in headcount, with 15 different nationalities represented in the workforce community. Lenovo has subsequently been recognized with an award from the Hungarian Ministry of Foreign Trade for creating the most jobs in the country. Through the Lenovo Foundation, the company’s philanthropic arm, the facility has also formally partnered with the local community to provide volunteer work and technology to local schools, as well as take part in monthly blood donations in partnership with the Hungarian Red Cross Foundation.
The Budapest manufacturing facility was built with sustainability in mind and since opening has increased the building heating isolation, completed installation of a lighting sensor systems, and optimized air compressor waste heat utilization. The second phase of solar panel installation is now underway to increase capacity to 4 megawatts, which produces the equivalent amount of power of approximately 12 fuel tanker trucks of natural gas. Throughout the year, heat from across the production house is rerouted to keep the manufacturing space warm. In winter, cold air from outside the facility is used for cooling purposes, and expansion of this process is now planned throughout the factory. Reusing heat in this way has decreased energy costs by 14%.
With a goal of reaching net-zero greenhouse gas emissions across the value chain by FY2049/50, Lenovo has seen CO2 emissions on shipments decrease by more than 90% due to reduced freight miles, thanks to the facility’s location at the center of Europe. This combined with innovative manufacturing processes, such as Lenovo’s patented low-temperature solder process, is helping the company work towards achieving its science-based climate goals.
As the leading provider on the TOP500 list of supercomputers for the last five years, Lenovo has continued to service customers hosting some of Europe’s largest supercomputers, with added capabilities from the Hungary facility. This includes the Barcelona Supercomputing Center in Spain, Leibniz Supercomputing Center in Germany, and SURF in the Netherlands, amongst many other high-performance computing centers.
The Hungary facility is part of Lenovo’s global manufacturing of 35 sites across eight markets that serve customers in 180 markets – including Argentina, Brazil, China, Hungary, India, Japan, Mexico and the USA. Lenovo is widely recognized for its global hybrid manufacturing model that includes a mix of both in-house and contract manufacturing.
About Lenovo:
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$62 billion revenue global technology powerhouse, ranked #171 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230621848074/en/
Contact information
Ella Hulbert - ehulbert@lenovo.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom